Company: BGLC
Filing Date: 2025-11-14
Form Type: PRE 14A
Source: 0001477932-25-008317
Chunk: 13

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: PRE 14A
Chunk 13
---
 career in merchant banking and brings his considerable experience to the role and as a result, the Company believes he is qualified to be a member of the Board.

| 9 |

Board Committees and Director Independence

Director Independence

We have determined that Mr. Chee Keong Yap, Mr. Muhammad Azrul bin Abdul Hamid, and Ms. Jook Yuen Low, are “independent” as defined by the Nasdaq Rule 5605(a)(2). Accordingly, a majority of our Board is “independent.” There are no family relationships among any of our directors or executive officers.

Board Committees

Our Board has established three standing committees – Audit, Compensation, and Nominating and Corporate Governance. All standing committees operate under a charter that has been approved by our Board.

Audit Committee

Our Board of Directors has an Audit Committee, composed of Chee Keong Yap, Muhammad Azrul bin Abdul Hamid, and Jook Yuen Low. All members are independent directors as defined in accordance with Rule 10A-3 of the Exchange Act and the Nasdaq Listing Rules. Mr. Yap serves as Chairman of the committee.

Our Audit Committee oversees our corporate accounting, financial reporting practices and the audits of financial statements. For this purpose, the Audit Committee has a charter (which is reviewed annually) and performs several functions. The Audit Committee:

| · | Evaluates the independence and performance of, and assesses the qualifications of, our independent auditor and engages such independent auditor;                                                                                                                                                             |
| · | Approves the plan and fees for the annual audit, quarterly reviews, tax and other audit related services and approves in advance any non-audit service and fees therefor to be provided by the independent auditor;                                                                                          |
| · | Monitors the independence of the independent auditor and the rotation of partners of the independent auditor as required by law;                                                                                                                                                                             |
| · | Reviews the financial statements to be included in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and reviews with management and the independent auditors the results of the annual audit and reviews of our quarterly financial statements;                                             |
| · | Oversees all aspects of our systems of internal accounting and financial reporting control and corporate governance functions on behalf of the Board; and                                                                                                                                                    |
| · | Provides oversight assistance in connection with legal, ethical and risk management compliance programs established by management and the Board, including compliance with requirements of Sarbanes Oxley and makes recommendations to the Board regarding corporate governance issues and policy